Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Of Amber Peripheral Liquid Embolic System: a First-in-HumAn & PivotaL Study

NCT06456125 is registered in ClinicalTrials.gov with LVD Biotech S.L as lead sponsor.

NCT NCT06456125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06456125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Of Amber Peripheral Liquid Embolic System: a First-in-HumAn & PivotaL Study
Lead sponsor
LVD Biotech S.L
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 12, 2024
Completion date
December 31, 2026
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aneurysm, hemorrhage, hypervascular tumor, pathological organ, portal vein embolization, pseudoaneurysm, type ii endoleak, varicose veins, vascular anomalies